Elevation Oncology, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial for the treatment of advanced solid tumors harboring a neuregulin-1 fusion. Elevation Oncology, Inc. was incorporated in 2019 and is based in New York, New York.
Over the last 12 months, insiders at Elevation Oncology, Inc. have bought $0 and sold $0 worth of Elevation Oncology, Inc. stock.
On average, over the past 5 years, insiders at Elevation Oncology, Inc. have bought $26M and sold $2.9M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 187,500 shares for transaction amount of $3M was made by Aisling Capital IV, LP (10 percent owner) on 2021‑06‑29.
2022-05-25 | Sale | 702,737 3.1622% | $4.12 | $2.9M | -69.80% | |||
2021-06-29 | 10 percent owner | 187,500 22.5074% | $16.00 | $3M | -56.00% | |||
2021-06-29 | 10 percent owner | 625,000 75.0247% | $16.00 | $10M | -56.00% | |||
2021-06-29 | 10 percent owner | 312,500 37.5123% | $16.00 | $5M | -56.00% | |||
2021-06-29 | 10 percent owner | 250,000 30.0099% | $16.00 | $4M | -56.00% | |||
2021-06-29 | 250,000 30.0099% | $16.00 | $4M | -56.00% |
Aisling Capital IV, LP | 10 percent owner | 2834910 4.7953% | $0.60 | 1 | 0 | <0.0001% |
venBio Global Strategic Fund III, L.P. | 10 percent owner | 2608167 4.4117% | $0.60 | 1 | 0 | <0.0001% |
Qiming U.S. Healthcare Fund II, L.P. | 10 percent owner | 2370142 4.0091% | $0.60 | 1 | 0 | <0.0001% |
Vertex Global HC Fund II Pte. Ltd. | 10 percent owner | 2307642 3.9034% | $0.60 | 1 | 0 | <0.0001% |
Cormorant Asset Management, LP | 2233168 3.7774% | $0.60 | 1 | 0 | <0.0001% |
Farallon Capital | $19.94M | 7.11 | 3.89M | New | +$19.94M | 0.14 | |
Point72 Asset Management | $17.28M | 6.17 | 3.37M | New | +$17.28M | 0.03 | |
Tang Capital Management, LLC | $15.7M | 5.6 | 3.06M | -16.57% | -$3.12M | 0.06 | |
Balyasny Asset Management Llc | $15.67M | 5.59 | 3.06M | New | +$15.67M | 0.04 | |
Aisling Capital Management LP | $14.54M | 5.19 | 2.83M | 0% | +$0 | 4.98 |